Myocardial function and structure improvement with sacubitril/valsartan in cancer therapy-induced cardiomyopathy
Rev Esp Cardiol (Engl Ed). 2020 Mar;73(3):268-269.
doi: 10.1016/j.rec.2019.07.006.
Epub 2019 Aug 12.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Cardiología, Hospital Universitario de Salamanca-IBSAL, Universidad de Salamanca, Salamanca, Spain; CIBERCV, Instituto de Salud Carlos III, Madrid, Spain. Electronic address: anamartin.amg@gmail.com.
- 2 Servicio de Cardiología, Hospital Universitario de Salamanca-IBSAL, Universidad de Salamanca, Salamanca, Spain.
- 3 Philips Healthcare, Madrid, Spain.
- 4 CIBERCV, Instituto de Salud Carlos III, Madrid, Spain; Laboratorio Traslacional para la Imagen y Terapia Cardiovascular, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Servicio de Cardiología, Fundación Jiménez Díaz Hospital, Madrid, Spain.
- 5 Servicio de Cardiología, Hospital Universitario de Salamanca-IBSAL, Universidad de Salamanca, Salamanca, Spain; CIBERCV, Instituto de Salud Carlos III, Madrid, Spain.
No abstract available
MeSH terms
-
Aged
-
Aminobutyrates / adverse effects*
-
Biphenyl Compounds
-
Cardiomyopathies / chemically induced
-
Cardiomyopathies / diagnosis
-
Cardiomyopathies / physiopathology*
-
Drug Combinations
-
Female
-
Humans
-
Male
-
Myocardial Contraction / drug effects*
-
Myocardial Contraction / physiology
-
Neoplasms / drug therapy*
-
Stroke Volume / drug effects*
-
Tetrazoles / adverse effects*
-
Valsartan
Substances
-
Aminobutyrates
-
Biphenyl Compounds
-
Drug Combinations
-
Tetrazoles
-
Valsartan
-
sacubitril and valsartan sodium hydrate drug combination